Background: Osteopetrosis encompasses a group of rare metabolic bone diseases characterized by impaired osteoclast activity or development, resulting in high bone mineral density. Existing guidelines focus on treatment of the severe infantile forms with hematopoietic cell transplantation (HCT) but do not address the management of patients with less severe forms for whom HCT is not the standard of care. Therefore, our objective was to develop expert consensus guidelines for the management of these patients.
O steopetrosis is a group of rare bone disorders, within the family of sclerosing bone dysplasias, characterized by reduced osteoclastic bone resorption that results in a high bone mass. Rather than conferring strength, the overly dense bone architecture belies a structural brittleness that predisposes to fracture. The disruption of normal bone modeling and remodeling can give rise to skeletal deformity and dental abnormalities and can interfere with mineral homeostasis. In addition, expansion of bone into marrow cavities and cranial nerve foramina can compromise hematologic and neurologic function, respectively; the former may manifest as profound anemia, bleeding, frequent infections, and hepatosplenomegaly from extramedullary hematopoiesis. The latter can lead to blindness, deafness, and nerve palsies (1) .
Not every patient is affected in the same way. Osteopetrosis comprises a clinical spectrum ranging from very mild to severe disease phenotypes that are fatal in the first year of life. Osteopetrosis has for decades been categorized descriptively by its clinical severity and inheritance pattern into a "malignant" autosomal recessive infantile form, a "benign" adult autosomal-dominant form (which can be severe), and an intermediate form.
The incidence is variably estimated at 1:200,000 for autosomal-recessive osteopetrosis (2) and 1:20,000 for autosomal-dominant osteopetrosis (3) . Recent molecular and genetic advances have begun to clarify the molecular basis of the disease and now allow the classification of osteopetrosis by its underlying molecular pathogenesis. The identification of specific genetic mutations can yield important prognostic and therapeutic implications (see following section on Genetic Testing). Unfortunately, incomplete penetrance and variable expressivity contribute to the wide phenotypic spectrum that can be seen even within kinships (4) , limiting the ability to correlate the genotype and clinical phenotype.
The rarity and heterogeneity of osteopetrosis can present substantial challenges to clinicians. Existing consensus guidelines by the European Society for Immunodeficiencies and the European Society for Blood and Marrow Transplantation Inborn Errors Working Party provide a framework for the diagnosis, treatment, and follow-up of patients with infantile osteopetrosis, but they focus largely on the indications for, approaches to, and complications of hematopoietic cell transplantation (HCT) (5) . They notably do not address the very different clinical course and treatment of patients with relatively milder forms of osteopetrosis, which can still be associated with substantial morbidity. Therefore, the objectives of these consensus guidelines are to summarize the collective experience of our panel of experts and provide a basis for standardizing the diagnostic approach and medical management of patients with noninfantile forms of osteopetrosis.
Methods

Methods for developing consensus recommendations
We began by formulating open-ended questions to elicit the minimum criteria for diagnosis, necessary baseline studies, practice patterns, monitoring strategies, and referral indications for specific medical subspecialties and for HCT. We distributed this survey electronically, inviting members of the Osteopetrosis Working Group, which consists of endocrinologists, geneticists, orthopedic surgeons, hematologists, and blood and marrow transplant physicians, to participate. Responses were collected anonymously and analyzed for areas of agreement and conflict; questions were then revised and recirculated for a second round of input from our experts. A summary of collective responses from the first round was also included, and participants were given an opportunity to rate their agreement with the suggestions of their peers. In this way, a modified Delphi method was used to build consensus.
Methods for developing evidence-based recommendations
We conducted a systematic review of the literature on osteopetrosis to ensure that our consensus guidelines were not only founded on expert opinion but also were evidence-based when possible. English-language publications with abstracts available and pertaining to humans from January 1970 to January 2017 were collected by searching PubMed using the keyword "osteopetrosis." Additional publications were then added to this collection on the basis of relevant citations in those publications.
We applied the Grading of Recommendations Assessment, Development and Evaluation system (6) to weigh the quality of evidence and strength of our recommendations. Because osteopetrosis is a rare disease, the body of literature is sparse and composed primarily of case reports and case series. High-quality evidence in the form of randomized controlled trials and metaanalyses is lacking. The strength of each recommendation was indicated as 1 (strong recommendation) or 2 (weak recommendation). The quality of the evidence was indicated by crossfilled circles, such that Åsss denotes very-low-quality evidence; ÅÅss, low quality; ÅÅÅs, moderate quality; and ÅÅÅÅ, high quality.
Diagnosis
Imaging
We recommend that demonstration of the classic radiographic features (Fig. 1) of osteopetrosis is the minimum needed to make the diagnosis (1|ÅÅÅs).
Osteopetrosis, derived from the Greek words for "bone" ("osteo") and "stone" ("petros"), is a fitting name for a disease in which generalized osteosclerosis identifiable on standard radiographs is pathognomonic. Parallel bands of dense bone can give the appearance of "bone-within-bone" or "endobones." This finding is often prominent in the pelvis, long bones, phalanges, and vertebrae. Vertebrae can also be uniformly dense or take on a "sandwich vertebrae" or "rugger-jersey" appearance (when a normal-appearing vertebral midbody is sandwiched between dense bands along the superior and inferior endplates). Club-shaped flaring of the metaphyses of long bones with cortical thinning (Erlenmeyer flask bone deformity) and transverse metaphyseal lucent bands reflect a failure of metaphyseal remodeling but are not exclusive to osteopetrosis (7) . Evidence of new or healing fractures may be found, and skull changes can include calvarial and basilar thickening as well as poor sinus development.
Because of the wide gamut of pathognomonic radiographic features of osteopetrosis, a skeletal survey is sufficient to make the diagnosis.
Genetic testing
We recommend genetic testing once the radiographic diagnosis of osteopetrosis has been established because it can distinguish among forms of osteopetrosis with unique complications (1|ÅÅÅs).
Before osteoclasts can achieve bone resorption, they must first embark on a path (Fig. 2 ) that involves differentiation from granulocyte-macrophage precursors, attachment to bone, creation of a ruffled border (resorptive surface), and acidification of the bone to dissolve and digest the mineral matrix. The last step requires the generation of protons by carbonic anhydrase II (CAII), transport of protons through the ruffled border by a vacuolar proton pump, and maintenance of electroneutrality in the ruffled border by chloride exchange (1) . Most defects in osteopetrosis represent loss-of-function mutations that impair the acidification process through trafficking and/or fusion of lysosome-related organelles to the ruffled border. (8) . On the other hand, mutations in tumor necrosis factor ligand superfamily member 11 (TNFSF11, MIM 602642) and tumor necrosis factor receptor superfamily member 11A (TNFRSF11A,MIM 603499) are associated with osteoclast-poor forms of autosomal recessive osteopetrosis by interfering with the receptor activator of nuclear factor k-B receptor and ligand signaling pathway through which osteoblasts activate osteoclastogenesis. Genetic testing may provide critical information on prognosis and clinical associations that have a meaningful effect on management decisions. CAII deficiency presents with a constellation of renal tubular acidosis and cerebral calcifications, and special attention needs to be paid to the potential for nephrocalcinosis and nephrolithiasis. HCT provides great potential as a means of remodeling the bony changes associated with osteopetrosis, because repopulating the marrow with the necessary hematopoietic precursors allows recovery of functional osteoclasts. However, this holds true only for mutations intrinsic to the osteoclast. Therefore, although the TNFRSR11A and TNFSF11 mutations both lead to an osteoclast-poor phenotype, HCT can treat the former but not the latter because nuclear factor k-B receptor is expressed on osteoclasts, whereas nuclear factor k-B receptor ligand is produced by cells of mesenchymal origin. OSTM1 defines a rare subset of patients with very severe central nervous system involvement marked by cerebral atrophy and loss of myelination, such that even though their osteoclast defect might be rescued by HCT, their extremely short life expectancy limits the utility of this approach. On the other hand, CLCN7 mutations of the chloride transporter are responsible for a wide range of clinical presentations within the infantile autosomal-recessive, "benign" autosomaldominant, and intermediate forms of osteopetrosis. Thus, identification of a CLCN7 mutation provides little information on how the disease will progress. Molecules affecting osteoclast differentiation and function. The binding of receptor activator of nuclear factor k-B (RANK) ligand (RANKL) produced by osteoblasts to RANK on osteoclast precursors induces osteoclast differentiation; in animals with defects in these genes, no osteoclasts are observed. In disorders of acidification-including defects in carbonic anhydrase II (CAII), the osteoclast-specific proton pump (encoded by TCIRG1, also termed ATP6i), and the gene encoding a chloride channel (CLCN7)-there are no primary defects in differentiation. 
Management Guidelines
Baseline and monitoring studies
Laboratory evaluations
Once osteopetrosis has been diagnosed, we recommend obtaining minimum initial studies of serum calcium, intact parathyroid hormone, phosphorus, creatinine, 25-hydroxyvitamin D [25(OH)D], complete blood count with differential, creatine kinase isoenzymes (specifically the BB isozyme of creatine kinase), and lactate dehydrogenase (1|ÅÅss) ( Table 1) .
Serum calcium, phosphorus, 25(OH)D, and intact parathyroid hormone provide a measure of mineral homeostasis and can guide supplementation. A complete blood count with differential allows monitoring for evidence of bone marrow failure that may require transfusion, referral to a bone marrow transplant specialist, or other supportive measures.
In the absence of genetic testing or typical radiographic findings, elevated levels of lactate dehydrogenase, aspartate aminotransferase, tartrate-resistant acid phosphatase (not currently clinically available), as well as the BB isozyme of creatine kinase when normalized for age, have all been found to correlate with autosomal dominant osteopetrosis due to CLCN7 defects but not other sclerosing bone diseases (9-13). Nevertheless, levels of these biomarkers have not been shown to correlate with disease severity or elucidate carrier status (11, 14) , and normalcy does not rule out the presence of a mutation in CLCN7.
Imaging
In an effort to minimize radiation exposure, we recommend baseline magnetic resonance imaging of the brain to evaluate for cranial nerve involvement, hydrocephalus, and vascular abnormalities, followed by computed tomography if clinical findings of cranial nerve compression are identified (1|ÅÅss).
There is a high prevalence of optic nerve involvement reported in all forms of osteopetrosis (15, 16) ; the resultant visual impairment often has its onset early in life but can be variable. Although a patient who reportedly lost vision in the sixth decade of life has been briefly described (17), we (16) and others (18) have not observed visual impairment after growth cessation. Given the potential for progressive and severe disability, baseline neuroimaging with special attention to the optic foramina is warranted to enable early detection and treatment of these neurologic complications, which when present should be evaluated by an ophthalmologist every 6 months. The need for and frequency of subsequent imaging can then be guided by ophthalmologic findings.
We suggest that dual-energy x-ray absorptiometry (DXA) is not required as part of routine diagnosis or monitoring of disease progression (2|ÅÅss).
In patients with osteopetrosis, DXA reveals a markedly increased bone mineral density throughout the entire skeleton, especially at the lumbar spine, with increasing density with age pointing to the progressive nature of the disease (19) . Unfortunately, despite its utility in the general population, in which low bone mineral density/ osteoporosis is a risk factor for fracture, DXA cannot accurately predict the risk for fractures in patients with osteopetrosis (20) . This limits its utility in this population.
Bone biopsy
We suggest that a bone biopsy is not useful except in exceptional situations, such as when there is a need to distinguish between osteoclast-poor and osteoclast-rich osteopetrosis (2|ÅÅss).
Osteoclasts are often present in normal or even increased numbers in bone specimens from patients with some disease-causing mutations but are absent in others. Bone biopsy can distinguish between osteoclast-poor and osteoclast-rich subtypes of osteopetrosis. Although this invasive and technically challenging study may have guided treatment options in the previous era, it now offers little that genetic testing cannot provide and is therefore rarely performed.
Multidisciplinary approach
Optimal care of patients with osteopetrosis requires the involvement of a multidisciplinary team that, depending on mutation and clinical comorbidities, may include specialists in endocrinology, ophthalmology, genetics, dentistry, orthopedic surgery, neurology, neurosurgery, otolaryngology, hematology, infectious disease, nephrology, pain management, and developmental pediatrics ( Table 2 ). We recommend evaluations for all patients by specialists in endocrinology, ophthalmology, genetics, and dentistry at the time of initial diagnosis (1|ÅÅss).
Endocrinology
The human skeleton as a reservoir comprises .99% of the total body calcium, which it can store or release under the tightly regulated influence of hormones, principally parathyroid hormone and vitamin D, to maintain serum levels within the physiologic range. In osteopetrosis, defective osteoclast activity renders the bone unable to mobilize its calcium pool and participate in normal calcium homeostasis, giving rise to hypocalcemia and resultant tetany and seizures. Paradoxically, despite the markedly positive total body calcium and phosphate balances in osteopetrosis, having mineral stores locked away in this manner also deprives the body of the substrate it needs to mineralize newly formed bone, which can result in rickets in autosomal-recessive osteopetrosis, otherwise aptly known in this setting as osteopetrorickets (21) . Many of these complications pertaining to mineral balance can be effectively managed by the endocrinologist, who can direct calcium, phosphate, and vitamin D therapy, including the use of calcitriol when indicated, and monitor bone development.
Ophthalmology
Ocular complications are especially prevalent and severe in autosomal-recessive infantile osteopetrosis [affecting half of patients with a median age of 2 months at onset in one case series (15) ] but do also frequently develop in patients with less severe forms of osteopetrosis as well (17, 22) . The most common complication is optic nerve atrophy, resulting in visual impairment (22, 23) . Although vision loss has in some cases been attributed to processes unrelated to bony changes, including retinal degeneration and impaired optic nerve myelination (24), the primary mechanism by which patients develop optic atrophy appears to be extrinsic nerve compression by the surrounding optic foramen (17, (24) (25) (26) (27) . A comprehensive ophthalmologic evaluation together with monitoring of visual evoked potentials can allow early detection of visual dysfunction, prompt necessary investigations, and facilitate timely intervention. Dedicated CT can evaluate patency of the optic canals and confirm optic nerve entrapment, and electroretinography can determine whether pathology originates at the retina rather than the optic nerve (28, 29) . It is important to note that many patients can be asymptomatic at diagnosis but have vision loss that is slowly progressive (2).
Dentistry
It is not surprising that many cases of osteopetrosis are first identified by dentists because the range of dental abnormality includes tooth agenesis, a delay or failure of tooth eruption, enamel hypoplasia, malformed crowns and roots, and tooth loss due to early decay and caries (Table 2) (30, 31) . Osteomyelitis in osteopetrosis most frequently occurs in the mandible, where it typically follows odontogenic infections and oral procedures, may leave necrotic bone exposed, and is notoriously difficult to eradicate (32) because of a reduced blood supply and often accompanying anemia and neutropenia. Surgical debridement and antibiotics are the mainstays of therapy, whereas refractory cases may require hyperbaric oxygen to promote local healing and reperfusion (33) . Tooth extraction should be approached judiciously because carious teeth can be precursors to osteomyelitis, but the operation itself can also induce infection, fractures, and other sequelae of poor healing, including irregular alveolar ridges (34) . Routine dental surveillance and maintenance of proper oral hygiene by the dentist in this high-risk population is of utmost importance and can prevent, identify, and manage the myriad complications.
Orthopedics
When bone resorption is hampered and bone formation proceeds unopposed, as occurs in osteopetrosis, both the quantity and quality of bone suffer-total bone mass increases (35) but is distributed unevenly (20) , and haphazard woven bone and calcified cartilage remnants of primary spongiosa can be seen histologically (36) . The resulting fragility makes fracture a frequent problem for patients with osteopetrosis. Osteopetrotic bone fails under tensile stress (fractures occur at right angles to the cortex) rather than compressive stress (37) , reflected in the fact that vertebral compression fractures have not been reported (38) . Fractures are particularly common in autosomal-dominant CLCN7-deficient osteopetrosis and were the most common complication overall in two large case series (16, 18) , routinely involving long bones, such as the proximal femur. The material properties of osteopetrotic bone make operative repair particularly challenging; the combined hardness and brittleness is resistant to drilling and prone to iatrogenic fracture, reduces the bone's ability to hold screws, and can necessitate creation of a medullary cavity for intramedullary fixation (39, 40) . The postoperative course can be further complicated by defective remodeling, implant failure, and refracture risk; osteomyelitis can follow and often requires aggressive surgical debridement and en bloc resection. In some cases, fractures can be appropriately treated nonoperatively, although they should be monitored carefully for delayed union and nonunion as well as disabling deformities, including coxa vara and lateral bowing of the femur and long bones (38) . For these reasons, the orthopedic surgeon should be consulted for any fractures and skeletal deformities.
Neurology and neurosurgery
The most prevalent neurologic complications of osteopetrosis are the compressive neuropathies that stem from progressive constriction of cranial foramina and/or the failure of these foramina to enlarge proportionately with growth. The optic nerve is disproportionately affected in patients with autosomal-recessive osteopetrosis, whereas the most frequent cranial nerve deficit in autosomal-dominant CLCN7-deficient osteopetrosis is the facial nerve (22, 41, 42) , followed by the acoustic nerve, although any of cranial nerves I through VIII can be involved (43) . Many of the cranial palsies can be subclinical (41) and are detected only on careful evaluation or after they have progressed. Optic nerve decompression (17, 25) and optic nerve sheath fenestration (44) in the appropriate clinical settings have been demonstrated to improve visual function and may better preserve visual acuity if performed early (45) , although it is important to note that such positive outcomes are not universal (28, (46) (47) (48) and can be difficult to achieve in very young patients. Successful results have also been reported to follow decompression of the facial and acoustic nerves (49) , although these operations are not without their risks and limitations (42) .
Less commonly reported are the consequences of calvarial thickening reducing cranial capacity, which can include increased intracranial pressure, posterior fossa crowding, cerebellar tonsillar herniation, and hydrocephalus (45, 49) . Case reports have also described cerebrovascular stenosis and occlusion (51-55), craniosynostosis (56, 57) , and Arnold-Chiari I malformation (58, 59) . Finally, neurologic disease is associated with some specific genetic mutations. Developmental delay or regression, unexplained seizures, and neuroradiologic findings should alert to the possibility of an OSTM1 mutation. The cognitive defects of CAII deficiency are more variable, but the calcifications involving the basal ganglia, thalami, and/or gray-matter junction are almost always present (60) . Altogether, the neurologist and neurosurgeon have a crucial part to play in recognizing and mitigating sources of disability in osteopetrotic patients, and the latter can provide the necessary surgical intervention when indicated.
Otolaryngology
Extrinsic bony compression can lead to sensorineural deafness in a manner similar to the other cranial nerve palsies already discussed, but the hearing deficits seen in osteopetrosis can also arise from one of several conductive mechanisms, including recurrent otitis media, narrowing of the bony portion of the eustachian tube, obliteration of the round and oval windows, and immobilization or bony replacement of the ossicles (23, 49) . The failure of bone modeling to enlarge bony cavities also applies to the midface, where narrowed and distorted nasal architecture along with poorly pneumatized sinuses contribute to the chronic nasal congestion with rhinorrhea and obligate mouth breathing (21, 61, 62) that can afflict patients with autosomal-recessive osteopetrosis; fortunately, some of these problems may improve with age (23) . Although some areas of focus may overlap with those of other specialists, the otolaryngologist can provide essential expertise in addressing the many head and neck manifestations of osteopetrosis.
Hematology
Because of encroachment of osteopetrotic bone on the marrow cavity, the presence of hepatosplenomegaly and early myeloid cells in the periphery often indicate the development of extramedullary hematopoiesis. This encroachment eventually results in bone marrow failure in severe phenotypes and may also be seen to some degree in dominant and intermediate disease; profound anemia may be apparent, and thrombocytopenia with subsequent hemorrhage and infectious complications may prove life-threatening. Although a small minority of patients may recover sufficient hematopoiesis spontaneously (63), patients may become transfusion dependent. Early evidence has suggested that hypersplenic hemolysis may contribute to the anemia and thrombocytopenia, but splenectomy is not typically performed or recommended and corticosteroids have shown inconsistent results (see following section on Treatment). A reticulocyte count and blood smear may provide insight into whether anemia is a production problem or whether there is sequestration. Given the complexities that can be involved, it would be prudent to enlist the services of a hematologist when attempting to tackle refractory blood dyscrasias in patients with osteopetrosis.
Infectious disease
Patients with osteopetrosis, depending on the severity of their disease, are at variably increased risk for infections. Impaired vascularity, concomitant anemia and leukopenia, and impaired healing are among the factors at play. Osteomyelitis, particularly of the mandible but also of the long bones, is well reported in the literature and often is tenacious and difficult to treat. The activation of neutrophils and their ability to mount a respiratory burst response may also be impaired in autosomalrecessive osteopetrosis (64) . The infectious disease specialist can therefore be a vital resource in coordinating appropriate antimicrobial therapy and overseeing chronic and recalcitrant infections.
Nephrology
Renal manifestations of osteopetrosis are not well documented, with the exception of those associated with CAII deficiency: renal tubular acidosis, nephrocalcinosis, and nephrolithiasis (65) . The nephrologist can be consulted to monitor and address specific concerns as they arise in patients with known CAII mutations.
Treatments
Calcium and ergocalciferol/cholecalciferol
We recommend calcium and vitamin D as first-line therapy for the treatment of hypocalcemia and secondary hyperparathyroidism in patients with osteopetrosis (1|ÅÅss). We suggest that calcium supplementation be considered when dietary intake is below daily recommended dietary allowances (2|ÅÅss). We suggest that vitamin D (i.e., ergocalciferol or cholecalciferol) be given to maintain 25(OH)D levels at .30 ng/mL (2|ÅÅss).
When the understanding of osteopetrosis was more limited, a strategy of limiting the amount of calcium available for mineralization was attempted in one case report that described use of a low-calcium diet (66) ; the addition of corticosteroids (for hematologic reasons) likely further interfered with gut absorption of calcium but together led to varying degrees of growth retardation. Calcium and vitamin D are frequently taken by patients with osteopetrosis, but their use outside osteopetrorickets is often not specifically discussed in the literature. No studies have addressed optimal calcium or vitamin D intake in patients with osteopetrosis. Given the many physiologic processes that depend on calcium and vitamin D sufficiency, their requirements in osteopetrosis should likely mirror those of the general population. A reasonable approach is to start standard age-appropriate doses of calcium and vitamin D replacement to meet recommended dietary allowances as outlined by the Institute of Medicine (67) .
The optimal concentration of 25(OH)D for skeletal and nonskeletal benefits remains a point of contention among professional societies and scientific organizations. The American Academy of Pediatrics (68) Osteopetrorickets most typically develops in patients with TCIRG1 mutations as a result of reduced gastric acidity, which in turn decreases calcium absorption; calcium supplementation may be sufficient to correct the bony and metabolic abnormalities in these patients. A case series of five osteopetrotic patients with biochemical (low calcium and phosphorus levels, high alkaline phosphatase for age) and radiographic findings of rickets (rachitic rosary, appendicular metaphyseal enlargement) together with baseline calcium-phosphorus products ,30 mg 
Calcitriol
We suggest that calcitriol should not be used in high doses for treatment of osteopetrosis (2|ÅÅss).
Calcitriol is known to play a physiologic role in promoting the differentiation of osteoclasts from monocyte-macrophage stem cell precursors and in high doses can foster osteoclastic bone resorption by stimulating nuclear factor k-B ligand production by osteoblasts. In 1984, Key et al. (71) first described the treatment of an infant diagnosed with severe recessive osteopetrosis by using high-dose calcitriol (titrated up to 32 mg/d) along with a low-calcium diet (to prevent hypercalcemia), resulting in improvements in measures of osteoclast and monocyte function. Despite these seemingly encouraging findings, the patient continued to deteriorate and calcitriol was ultimately withdrawn after 3 months because of poor neurologic prognosis. Subsequent case reports using high-dose calcitriol to stimulate bone resorption have similarly failed to demonstrate any meaningful clinical benefit in bone resorption or hematologic recovery (72) (73) (74) . Animal studies have shown that not only does calcitriol not increase osteoclastic bone resorption (75, 76) but it may also have the opposite intended effect of increasing bone mass (77) . Calcitriol at high doses has thus largely fallen out of favor given that any advantages are anecdotal at best.
Red blood cell transfusion
The decision for transfusion of red blood cells (RBCs) is recommended to be guided by the presence of symptomatic anemia as well as the hemoglobin level in consultation with a hematologist (1|ÅÅss).
RBC transfusions are not benign and can lead to several adverse outcomes. Any decision to transfuse should first trigger a clinical evaluation that accounts for such factors as baseline hemoglobin level, the rate of decline in hemoglobin level, intravascular volume status, existing cardiovascular conditions, and alternative therapies and should proceed only if the benefits outweigh the risks.
In hemodynamically stable adult patients in the inpatient and critical care settings, we agree with a restrictive threshold by which RBC transfusion is not indicated until the hemoglobin level is #7 g/dL. These recommendations are in line with those from multiple societal guidelines, including those from the AABB (formerly known as the American Association of Blood Banks) published in 2016 (78) , which are, in turn, derived from now 31 randomized clinical trials examining hemoglobin thresholds for RBC transfusion demonstrating that a restrictive transfusion strategy is as safe as a liberal one that treats at hemoglobin levels of #10 g/dL. A randomized controlled trial in stable critically ill children drew similar conclusions and suggests that this threshold might apply to pediatric populations as well (79) .
Interferon g-1b
We suggest that the use of interferon g-1b be considered experimental in noninfantile osteopetrosis (2|ÅÅss).
Early studies in autosomal-recessive osteopetrosis demonstrated a defect in nitroblue tetrazolium reduction and decreased intracellular bacterial killing among leukocytes (64, 80) , suggesting that dysfunctional superoxide generation might contribute to the susceptibility to infections. Leukocytes and osteoclasts were recognized to arise from a common hematopoietic precursor, and subsequent studies found that osteoclasts also relied on superoxide generation to resorb bone (81) and that osteoclasts from an osteopetrotic patient exhibited similar deficits in oxygen radical formation (82) . Breakthroughs from chronic granulomatous disease in which interferon g-1b increased superoxide production and improved clinical outcomes led to trials of this agent in patients with autosomal-recessive osteopetrosis that revealed not only increases in leukocyte superoxide activity but also hematologic recovery and decreases in trabecular bone volume after up to 18 months of therapy (83, 84) , although the desired benefits are not always seen (74) . These findings culminated in the U.S. Food and Drug Administration approval for the use of interferon g-1b (Actimmune; Horizon Pharma, Lake Forest, IL) in severe malignant osteopetrosis in 2000. Of note, that indication pertains only to severe infantile osteopetrosis at this time. Clinical experience with this therapy remains limited; however, clinical trials are under way to better clarify the role of interferon g-1b in the noninfantile osteopetrosis patient population.
Corticosteroids
Corticosteroid therapy may be considered as a secondline therapy to HCT in cases of severe infantile osteopetrosis in whom HCT is determined to not be appropriate (2|ÅÅss).
A reduced RBC survival time (85) , excess of nucleated RBCs, reticulocytosis, and absence of hemolyzing antibodies (86) in early studies seemed to implicate a hemolytic anemia (87) from hypersplenism in autosomalrecessive osteopetrosis, for which trials of corticosteroids (26, 66) and splenectomy (66, 86) benefited the anemia and thrombocytopenia in some but not all cases. Perhaps the most promising evidence comes from two case reports of infantile osteopetrosis, followed for 3 months and 3 years, treated in the newborn period with prednisone; spontaneous remission occurred, obviating the need for HCT (although mutation analysis does not appear to have been done) (88, 89) . Nevertheless, the mechanisms by which corticosteroids rectify the hematologic abnormalities have never been fully understood, and other studies have shown a variable response at best and no alteration in the natural course of the disease (29, 90) . In addressing the bone pathology, corticosteroids have a known osteoporotic effect by directly interfering with mineralization of bone and cartilage (91) and intestinal calcium absorption (90, 92) . However, given the present knowledge of the primarily osteoclastic acidification defects that generate the disease phenotype, the mineralization deficiencies that already exist with impaired turnover of bone, the generally transient effects, and the potential for adverse events, including growth delay, there is insufficient evidence to support the routine use of corticosteroids in osteopetrosis at this time.
Referral for HCT
Bone marrow failure and age ,1 year at diagnosis are primary indications to refer to a specialized center with experience in HCT treatment of patients with osteopetrosis. Genetic testing may reveal specific mutations that favor or preclude (e.g., OSTM1 or RANKL mutations) bone marrow transplantation. Neurologic involvement and unremitting pain may be reasonable indications to warrant an evaluation as well.
A detailed discussion of HCT is outside the scope of these guidelines; however, a few key points merit emphasis. Historically the best outcomes have been achieved by using a genotypically HLA-identical bone marrow donor (93), which is not commonly available. Serious limitations include high mortality rates within the first year (93, 94) . Importantly, HCT is an option only for mutations intrinsic to the osteoclast and remains experimental for intermediate osteopetrosis at this time. Each individual case warrants careful consideration of the risks vs benefits through consultation with an experienced HCT physician before proceeding with transplantation.
Conclusions/Future Directions
Scarcity of published studies on noninfantile osteopetrosis reduces the ability to develop evidence-based guidelines for the clinical management of these patients. Despite this limitation, the current effort is important to highlight the evidence that does exist and how it can be used within the medical community in a fashion that, although not completely evidence based, is at least consistent with known physiologic principles.
Studies on disease progression and effects of current supportive therapies are desperately needed. Despite an extensive literature review, most of our recommendations are based solely on expert opinion and, in some areas, small case series. A multicenter, longitudinal study of a large cohort of patients with noninfantile osteopetrosis is needed to better define disease progression, quantify response to current supportive therapies, and provide natural history data to be used in future therapeutic clinical trials. In addition, because noninfantile osteopetrosis has no cure, future research should also focus on curative therapies for this devastating disease.
